Ubs Group Ag Brainstorm Cell Therapeutics Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 2,501 shares of BCLI stock, worth $5,702. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,501

Previous 7,110 64.82%

Holding current value

$5,702

Previous $2,000 100.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.22 - $0.42 $1,013 - $1,935	-4,609 Reduced 64.82%	2,501 $0
Q2 2024 Aug 13, 2024	BUY	$0.34 - $0.74 $1,567 - $3,411	4,610 Added 184.4%	7,110 $2,000
Q4 2023 Feb 09, 2024	SELL	$0.15 - $0.4 $171 - $456	-1,140 Reduced 31.32%	2,500 $0
Q3 2023 Nov 09, 2023	BUY	$0.2 - $2.08 $228 - $2,371	1,140 Added 45.6%	3,640 $0
Q2 2023 Aug 11, 2023	SELL	$2.0 - $3.2 $10,000 - $16,000	-5,000 Reduced 66.67%	2,500 $5,000
Q3 2022 Nov 10, 2022	SELL	$2.55 - $4.42 $752 - $1,303	-295 Reduced 3.78%	7,500 $33,000
Q2 2022 Aug 10, 2022	BUY	$2.71 - $3.6 $241 - $320	89 Added 1.15%	7,795 $22,000
Q1 2022 May 16, 2022	SELL	$2.92 - $4.19 $19,566 - $28,077	-6,701 Reduced 46.51%	7,706 $26,000
Q4 2021 Feb 14, 2022	BUY	$2.81 - $4.23 $9,551 - $14,377	3,399 Added 30.88%	14,407 $58,000
Q3 2021 Nov 15, 2021	SELL	$3.14 - $4.09 $9,420 - $12,270	-3,000 Reduced 21.42%	11,008 $37,000
Q2 2021 Aug 13, 2021	SELL	$3.01 - $4.01 $6,892 - $9,182	-2,290 Reduced 14.05%	14,008 $54,000
Q1 2021 May 12, 2021	BUY	$3.46 - $7.88 $17,210 - $39,195	4,974 Added 43.92%	16,298 $63,000
Q4 2020 Feb 11, 2021	BUY	$3.99 - $17.73 $11,267 - $50,069	2,824 Added 33.22%	11,324 $51,000
Q3 2020 Nov 12, 2020	SELL	$11.19 - $16.92 $94,499 - $142,889	-8,445 Reduced 49.84%	8,500 $144,000
Q2 2020 Jul 31, 2020	BUY	$4.42 - $12.66 $63,846 - $182,873	14,445 Added 577.8%	16,945 $190,000
Q3 2019 Nov 14, 2019	SELL	$3.54 - $4.48 $9,090 - $11,504	-2,568 Reduced 50.67%	2,500 $10,000
Q2 2019 Aug 14, 2019	BUY	$3.59 - $4.3 $18,194 - $21,792	5,068 New	5,068 $20,000
Q1 2019 May 14, 2019	SELL	$3.37 - $4.34 $6,581 - $8,476	-1,953 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.98 - $3.9 $4,267 - $5,584	1,432 Added 274.86%	1,953 $7,000
Q3 2018 Nov 14, 2018	BUY	$3.73 - $4.38 $1,943 - $2,281	521 New	521 $2,000
Q2 2018 Aug 14, 2018	SELL	$3.12 - $5.19 $4,839 - $8,049	-1,551 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$3.01 - $3.77 $1,050 - $1,315	-349 Reduced 18.37%	1,551 $5,000
Q4 2017 Feb 14, 2018	SELL	$2.96 - $4.42 $6,372 - $9,516	-2,153 Reduced 53.12%	1,900 $7,000
Q3 2017 Nov 14, 2017	BUY	$3.98 - $4.36 $7,323 - $8,022	1,840 Added 83.15%	4,053 $17,000
Q2 2017 Aug 14, 2017	SELL	N/A	-3,610 Reduced 62.0%	2,213 $9,000
Q1 2017 Nov 14, 2017	BUY	N/A	5,823	5,823 $25,000

Others Institutions Holding BCLI

# of Institutions

Shares Held

10.8M

Call Options Held

160K

Put Options Held

30.5K

View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $83.2M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

More about BCLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account